Long-Acting Injectable Buprenorphine in Correctional Settings:

MAT ECHO - Long-Acting Injectable Buprenorphine in Correctional Settings: Opportunities, Challenges, and Implementation

The New England ATTC, in partnership with Spectrum Health Systems, is hosting the next session of the fall series of the Advancing Medications for Addiction Treatment in Correctional Settings ECHO Program on October 16, 2025, with subject matter expert Jessica Norton, MA, LCMHC, MLADC.

The sixth session in our ECHO series on medications for addiction treatment within the correctional setting focuses on Long-Acting Injectable Buprenorphine (LAIB). The session will begin by laying the groundwork for an understanding of where LAIBs are currently being used in corrections and why uptake varies. Next, participants will explore key clinical and operational considerations when creating an LAIB program, such as patient selection, workflows, custody coordination, and continuity after release. 

This training will also weigh the potential benefits and limitations of LAIBs in corrections, taking into consideration factors like the implications for adherence, diversion, staff capacity, and patient outcomes. By examining LAIB from all angles, participants will gain a comprehensive understanding of the opportunities and challenges presented by LAIB implementation in correctional settings.

Learn more & register